Top View
- Covid-19: the Lost Lessons of Tamiflu
- The FDA-Approved Drug Cobicistat Synergizes with Remdesivir to Inhibit SARS-Cov-2 Replication
- Therapeutic Effectiveness of Interferon-Alpha 2B Against COVID-19: the Cuban Experience
- Drug Natural Product Infection # of References Corticosteroid
- Protease Inhibitors (Ritonavir and ASC09) in Clinical Trials to Treat COVID-19, the Illness Caused by the New Coronavirus (Table 1)
- Appendix B - Product Name Sorted by Applicant
- Fact Sheet for Health Care Provides
- Role of Lopinavir/Ritonavir in the Treatment of Covid-19: a Review of Current Evidence, Guideline Recommendations, and Perspectives
- Sofosbuvir with Daclatasvir and the Outcomes of Patients with COVID-19
- The Efficacy and Safety of Antivirus Drugs for COVID-19: a Systematic Review Muhammad Ardi Munir*1, Hendra Kuganda2, Amirah Basry3
- Antiviral Therapeutic Approaches for SARS-Cov-2 Infection: a Systematic Review
- Subcutaneous Injection of IFN Alpha-2B for COVID-19: an Observational Study Bo Wang1†, Diandian Li1†, Tao Liu2, Haohua Wang3, Fengming Luo1 and Yanbin Liu4*
- Treatment Options for Severe Acute Respiratory Syndrome, Middle East Respiratory Syndrome, and Coronavirus Disease 2019: a Review of Clinical Evidence
- Analysis of Clinical Pharmacist Interventions in the COVID-19 Units of a French University Hospital
- COVID-19 Issues Issue 3
- Medication of Hydroxychloroquine, Remdesivir and Convalescent Plasma During the COVID-19 Pandemic in Germany—An Ethical Analysis
- Effective Drugs Used to Combat SARS-Cov-2 Infection and the Current Status of Vaccines
- Covid-19: What Now for Remdesivir?
- New Approaches and Repurposed Antiviral Drugs for the Treatment of the SARS-Cov-2 Infection
- Nafamostat–Interferon-Α Combination Suppresses SARS-Cov-2 Infection in Vitro and in Vivo by Cooperatively Targeting Host TMPRSS2
- A Review on Remdesivir
- Antiviral Drugs Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection Triggering the Coronavirus Disease‑19 Pandemic Rashed Noor*
- Synergistic Interferon Alpha-Based Drug Combinations Inhibit SARS
- Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2019
- Therapeutic Options for the 2019 Novel Coronavirus (2019-Ncov)
- Global-PPS Protocol with Optional HAI Module – Jan 2021
- Search for SARS-Cov-2 Inhibitors in Currently Approved Drugs to Tackle COVID-19 Pandemia
- Fda Combating Covid-19 with Therapeutics
- Microorganisms
- The Efficacy and Safety of Favipiravir in Treatment of COVID-19
- Ensuring Continued Progress for Development of COVID-19 Therapeutics in Children
- Summary on Compassionate Use: Remdesivir Gilead
- Adverse Effects of Remdesivir, Hydroxychloroquine, and Lopinavir/Ritonavir When Used for COVID-19: Systematic Review and Meta-Analysis of Randomized Trials
- Sofosbuvir May Be a Potential Anti-SARS-Cov-2 Rdrp Drug
- 20219 WHO Living Guideline -Therapeutics and COVID-19
- Development of Remdesivir
- FDA Program Spurs Development of Therapeutics for COVID-19 in Children, Adults by William Otto M.D., FAAP; Rachit Chawla M.D., FAAP
- Remdesivir and Ledipasvir Among the FDA-Approved Antiviral Drugs Have Potential to Inhibit SARS-Cov-2 Replication
- Amantadine Inhibits SARS-Cov-2 in Vitro
- Molecular Mechanism of Action of Repurposed Drugs and Traditional
- Remdesivir from Wikipedia, the Free Encyclopedia
- Clinical Trials on Drug Repositioning for COVID-19 Treatment
- Veklury (Remdesivir) EUA Fact Sheet for Healthcare
- Can the COVID-19 Pandemic Disrupt the Current Drug Development Practices?
- Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: from Mechanistic Studies to Clinical Trials for COVID-19
- Treatment of COVID-19 with Remdesivir
- Guidance for the Format and Content of the Protocol of Non-Interventional Post-Authorisation Safety Studies
- Drug Interactions
- Assessment of Evidence for COVID-19-Related Treatments
- Are Antiviral Drugs Available to Treat COVID-19 Infections? by H
- Prioritizing Antiviral Drugs Against SARS-Cov-2 by Integrating Viral
- Anti Hepatitis C Viral Drugs Remdesivir and Uprifosbuvir Derivatives Are Better Inhibitors of SARS Cov2 RNA-Dependent RNA Polymerase Determined by Docking Studies
- Drugs Repurposed for COVID-19 by Virtual Screening of 6,218 Drugs and Cell-Based Assay
- Therapeutic Effectiveness of Interferon-Α2b Against COVID-19
- COVID-19 Drug Therapy Tim Smith, Pharmd, BCPS; Jennifer Bushek, Pharmd; Aimée Leclaire, Pharmd, BCPS; Tony Prosser, Pharmd
- Synergistic Interferon Alpha-Based Drug Combinations Inhibit SARS-Cov-2 and Other Viral Infections in Vitro
- Remdesivir As a Broad-Spectrum Antiviral Drug Against COVID-19
- Is Veklury (Remdesivir) Approved by the FDA to Treat COVID-19? A
- Unpacking the Effects of Adverse Regulatory Events: Evidence from Pharmaceutical Relabeling